Quick Answer
Avalo Therapeutics, Inc. reported Diluted EPS of $5.84 per share (loss) for fiscal year 2025.
Avalo Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.84 | +72.1% |
| 2024 | -$20.91 | +81.6% |
| 2023 | -$113.58 | +89.3% |
| 2022 | -$1063.00 | -88483.3% |
| 2018 | -$1.20 | -385.7% |
| 2017 | $0.42 | +122.5% |
| 2016 | -$1.87 | +60.3% |
| 2015 | -$4.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.19 | +22.6% | -14.1% |
| June 30, 2025 | -$1.92 | +86.4% | -53.6% |
| March 31, 2025 | -$1.25 | +99.1% | +55.8% |
| September 30, 2024 | -$2.83 | +89.5% | +79.9% |
| June 30, 2024 | -$14.07 | +90.0% | +90.0% |
| March 31, 2024 | -$141.14 | +30.8% | -426.1% |
| September 30, 2023 | -$26.83 | -7991.2% | +80.9% |
| June 30, 2023 | -$140.73 | -10097.8% | +31.0% |
- Avalo Therapeutics, Inc. showed an increase of +72.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2015–2025 period, Avalo Therapeutics, Inc.’s diluted eps has declined by 24.0% (from $4.71 per share (loss) to $5.84 per share (loss)).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: